Donald D Hunt

US Patent:

20020192229, Dec 19, 2002

Filed:

Dec 13, 2001

Appl. No.:

10/022286

Inventors:

David Flyer - Olney MD, US
Mark Ross - Charlottesville VA, US
Donald Hunt - Charlottesville VA, US
Forest White - Charlottesville VA, US
Victor Engelhard - Charlottesville VA, US
Ramila Philip - Charlottesville VA, US

International Classification:

A61K039/00
C07K007/08
C07K007/06

US Classification:

424/185100, 530/328000, 530/327000

Abstract:

The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of tuberculosis, and discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against tuberculosis. The peptide and/or proteins of the invention may be used as a therapeutic drug to stimulate the immune system to recognize and eliminate in infected cells or as a vaccine for the prevention of disease. Antibodies that react with the immunogens of the invention, as well as methods of using these antibodies for prevention and treatment of disease, are also disclosed.

US Patent:

20120177669, Jul 12, 2012

Filed:

May 4, 2010

Appl. No.:

13/318821

Inventors:

Suzanne L. Topalian - Brookeville MD, US
Florence Depontieu - Lyon, FR
Donald Hunt - Charlottesville VA, US
Jeffrey Shabanowitz - Charlottesville VA, US
Jie Qian - Bridgewater NJ, US
Victor Engelhard - Crozet VA, US
Angela Zaring - charlottesviille VA, US

Assignee:

UNIVERSITY OF VIRGINIA PATENT FOUNDATION - Charlottesville VA
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD

International Classification:

A61K 39/00
A61K 35/12
C07K 16/30
A61P 35/00
A61P 35/04
A61P 37/04
C12N 5/0784
C07K 7/08
C07K 14/74
C07K 14/47
G01N 33/566
C07K 7/06
C12N 5/0783

US Classification:

4241851, 530328, 4242771, 5303879, 5303873, 435375, 435325, 530326, 530327, 530405, 530325, 530324, 436501, 435 71

Abstract:

We characterized a total of 175 HLA-DR-associated phosphopeptides using sequential affinity isolation, biochemical enrichment, mass spectrometric sequencing and comparative analysis. Many were derived from source proteins which may have roles in cancer development, growth and metastasis. Most were expressed exclusively by either melanomas or transformed B cells, suggesting the potential to define cell type-specific phosphatome “fingerprints”. We generated HLA-DRβ1*0101-restricted CD4T cells specific for a phospho-MART-1 peptide identified in two melanoma cell lines. These T cells showed specificity for phosphopeptide-pulsed antigen presenting cells as well as for intact melanoma cells. MHC II-restricted phosphopeptides recognizable by human CD4T cells are potential targets for cancer immunotherapy.